Precision Biosciences (DTIL) Intangibles (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Intangibles of $1.1 million for Q1 2026, up 85.67% year-over-year from $607000.0 in Q1 2025, and down 3.34% quarter-over-quarter from $1.2 million in Q4 2025.
Precision Biosciences (DTIL) Intangibles (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Intangibles for 9 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles rose 85.67% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (up 85.67% YoY), while the FY2025 annual figure was $1.2 million, up 87.46% from the prior year.
- Intangibles retreated to $1.1 million in Q1 2026 per DTIL's latest filing, from $1.2 million in the prior quarter.
- Across five years, Intangibles topped out at $2.0 million in Q1 2022 and bottomed at $375000.0 in Q2 2024.
- Historically, Intangibles has averaged $1.0 million across 5 years, with a median of $977000.0 in 2023.
- Annual changes were most pronounced in 2024 — Intangibles tumbled 75.84% — and 2025, when it jumped 153.87%.
- Precision Biosciences' Intangibles stood at $731000.0 in 2022, then slumped by 45.28% to $400000.0 in 2023, then soared by 55.5% to $622000.0 in 2024, then jumped by 87.46% to $1.2 million in 2025, then slipped by 3.34% to $1.1 million in 2026.
- Business Quant data shows DTIL's Intangibles at $1.1 million in Q1 2026, $1.2 million in Q4 2025, and $985000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | 1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.09 Mn |
| Mar 31, 2026 | 1.13 Mn |
| Dec 31, 2025 | 1.17 Mn |
| Sep 30, 2025 | 985,000.00 |
| Jun 30, 2025 | 605,000.00 |
| Mar 31, 2025 | 607,000.00 |
| Dec 31, 2024 | 622,000.00 |
| Sep 30, 2024 | 388,000.00 |
| Jun 30, 2024 | 375,000.00 |
| Mar 31, 2024 | 386,000.00 |
| Dec 31, 2023 | 400,000.00 |
| Sep 30, 2023 | 977,000.00 |
| Jun 30, 2023 | 1.55 Mn |
| Mar 31, 2023 | 1.53 Mn |
| Dec 31, 2022 | 731,000.00 |
| Sep 30, 2022 | 1.97 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Mar 31, 2022 | 2.02 Mn |
| Dec 31, 2021 | 2.05 Mn |
| Sep 30, 2021 | 2.07 Mn |